WO2008145475A1 - Oral care composition - Google Patents
Oral care composition Download PDFInfo
- Publication number
- WO2008145475A1 WO2008145475A1 PCT/EP2008/055398 EP2008055398W WO2008145475A1 WO 2008145475 A1 WO2008145475 A1 WO 2008145475A1 EP 2008055398 W EP2008055398 W EP 2008055398W WO 2008145475 A1 WO2008145475 A1 WO 2008145475A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- poloxamer
- composition according
- compositions
- oral care
- amphoteric surfactant
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 229920001983 poloxamer Polymers 0.000 claims abstract description 20
- 150000003751 zinc Chemical class 0.000 claims abstract description 20
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960000502 poloxamer Drugs 0.000 claims abstract description 16
- 239000002280 amphoteric surfactant Substances 0.000 claims abstract description 15
- 239000003945 anionic surfactant Substances 0.000 claims abstract description 12
- 239000006260 foam Substances 0.000 claims description 9
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical group C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 7
- 229960003237 betaine Drugs 0.000 claims description 5
- 229920001451 polypropylene glycol Polymers 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 4
- 239000003906 humectant Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000001680 brushing effect Effects 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 229920001992 poloxamer 407 Polymers 0.000 claims description 2
- 229940044476 poloxamer 407 Drugs 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000606 toothpaste Substances 0.000 description 5
- 235000019606 astringent taste Nutrition 0.000 description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 4
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 4
- 239000011746 zinc citrate Substances 0.000 description 4
- 235000006076 zinc citrate Nutrition 0.000 description 4
- 229940068475 zinc citrate Drugs 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003082 abrasive agent Substances 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 229920000831 ionic polymer Polymers 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000035910 sensory benefits Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 229940034610 toothpaste Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- -1 aminefluorides Chemical compound 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-O carboxymethyl-[3-(dodecanoylamino)propyl]-dimethylazanium Chemical group CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)=O MRUAUOIMASANKQ-UHFFFAOYSA-O 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960003500 triclosan Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- GEZAUFNYMZVOFV-UHFFFAOYSA-J 2-[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphastannetan-2-yl)oxy]-1,3,2$l^{5},4$l^{2}-dioxaphosphastannetane 2-oxide Chemical compound [Sn+2].[Sn+2].[O-]P([O-])(=O)OP([O-])([O-])=O GEZAUFNYMZVOFV-UHFFFAOYSA-J 0.000 description 1
- TYBHZVUFOINFDV-UHFFFAOYSA-N 2-bromo-6-[(3-bromo-5-chloro-2-hydroxyphenyl)methyl]-4-chlorophenol Chemical compound OC1=C(Br)C=C(Cl)C=C1CC1=CC(Cl)=CC(Br)=C1O TYBHZVUFOINFDV-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229910018516 Al—O Inorganic materials 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- TXXIWPTXQBKYOE-UHFFFAOYSA-N OC(=O)CC(CC(O)=O)(OP(=O)=O)C(O)=O Chemical class OC(=O)CC(CC(O)=O)(OP(=O)=O)C(O)=O TXXIWPTXQBKYOE-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 1
- 229950010221 alexidine Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000002272 anti-calculus Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002882 anti-plaque Effects 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- HKCOOGQWXRQBHJ-UHFFFAOYSA-L azanium;zinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound N.[Zn+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O HKCOOGQWXRQBHJ-UHFFFAOYSA-L 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004075 cariostatic agent Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- AZSFNUJOCKMOGB-UHFFFAOYSA-K cyclotriphosphate(3-) Chemical compound [O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 AZSFNUJOCKMOGB-UHFFFAOYSA-K 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 239000003975 dentin desensitizing agent Substances 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 229960001774 octenidine Drugs 0.000 description 1
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229940094025 potassium bicarbonate Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 239000001472 potassium tartrate Substances 0.000 description 1
- 229940111695 potassium tartrate Drugs 0.000 description 1
- 235000011005 potassium tartrates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940084560 sanguinarine Drugs 0.000 description 1
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- YVDPOVXIRVBNAL-UHFFFAOYSA-J tetrapotassium;phosphonatooxy phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OOP([O-])([O-])=O YVDPOVXIRVBNAL-UHFFFAOYSA-J 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/90—Block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Definitions
- the present invention relates to oral care compositions comprising zinc salts and having superior sensory benefits.
- EP-Al-O 740 932 discloses a gel type dentifrice comprising a zinc salt which is more water soluble than zinc citrate.
- US 5,470,561 discloses an anti-plaque mouthwash comprising a zinc salt and triclosan.
- GB 2,052,978 discloses a toothpaste comprising zinc salts with glycine.
- US 5,632,972 discloses a method for minimising damage to gingival and periodontal tissue by delivering a first component comprising zinc and a second component comprising a bicarbonate.
- US 4 325 939 discloses an alkali metal or ammonium zinc citrate prepared for use in dental compositions and especially in mouthwash compositions.
- US 5,188,820 discloses oral compositions comprising a mixture of a stannous salt and a zinc salt such as zinc citrate.
- Oral care compositions comprising surfactants, such anionic, non-ionic, or amphoteric surfactants are also known in the art.
- 02/26203 (Henkel, 2002) discloses dental cleaning agents comprising surfactants or tensides in the form of a combination of anionic tensides, betaine tensides, and ethoxylated fatty acid-polyol monoesters.
- WO 95/01173 (Unilever, 1995) and US 6,169,118 (Unilever, 2001) disclose amphoteric surfactants in toothpaste compositions.
- compositions comprising non-ionic polymers, such as poly (ethylene glycol) - poly (propylene glycol) block co-polymers, known as "poloxamers”.
- non-ionic polymers such as poly (ethylene glycol) - poly (propylene glycol) block co-polymers
- polyoxamers Such compositions are described in US 6,187,295 (P&G, 2001) .
- oral care compositions comprising zinc salts that have superior sensory properties and other properties.
- toothpaste compositions that have superior texture, flavour, and reduced astringency without compromising sensory perceptions of foam quantity and foam quality.
- an oral care composition comprising a zinc salt, an anionic surfactant, an amphoteric surfactant, and a poloxamer.
- a method of cleaning the teeth comprising brushing with a composition according to the first aspect of the invention.
- compositions according to the invention are used to improve the in use foam quantity and/or quality of an oral care composition also comprising a zinc salt, an anionic surfactant and an amphoteric surfactant.
- the sensory benefits given by compositions according to the invention are found both in use and after use. We have found that compositions according to the invention are perceived to have good texture in use and also good foam quantity and foam quality. In addition, compositions according to the invention give high flavour intensities both in use and after use and low astringency after use. It is believed that these benefits are related to the particular combination of surfactants and non-ionic polymer selected for use in the compositions of the invention.
- compositions of the present invention may take any of the forms commonly used for such purpose; however, toothpastes are a particularly suitable form.
- the zinc salt used in accordance with this invention may give benefits associated with its anti-microbial properties, such as reduced gingivitis, plaque, sensitivity, and/or bad breath.
- compositions of the present invention A problem encountered with some prior art compositions comprising zinc salts has been a relatively high level of astringency. This problem, amongst others, is at least partially overcome by the compositions of the present invention.
- the zinc salt used in accordance with the invention is typically soluble in water, meaning that it has a solubility in water of at least 0.1 g/1 at 25°C.
- the zinc salt has a solubility in water at 25°C of at least 1 g/1 and more preferably at least 2 g/1.
- Particularly preferred zinc salts are zinc citrate, zinc sulphate, glycinate, and zinc chloride. Mixtures of zinc salts may also be employed.
- Zinc citrate is the most preferred zinc salt for use in the compositions of the invention.
- the total amount of zinc salts is typically from 0.1 to 10%, in particular from 0.5 to 5%, and especially from 1 to 3% by weight of the total composition.
- the anionic surfactant used in accordance with the invention is preferably an alkali metal alkyl sulphate, more preferably a sodium linear alkyl (Cio-Ci ⁇ ) sulphate, and most preferably sodium lauryl sulphate (SLS) . Mixtures of anionic surfactants may also be employed.
- the total amount of anionic surfactant is preferably from 0.1 to 10%, more preferably from 0.2 to 5%, and especially from 0.5 to 2% by weight of the total composition.
- amphoteric surfactant used in accordance with the invention is preferably a betaine, more preferably an alkylamidopropyl betaine (wherein the alkyl group is a linear Cio ⁇ Ci8 chain) , and most preferably is cocoamidopropyl betaine (CAPB) .
- CAPB cocoamidopropyl betaine
- the total amount of amphoteric surfactant is preferably from 0.1 to 10%, more preferably from 0.2 to 5%, and especially from 0.5 to 2% by weight of the total composition.
- the poloxamer used in accordance with the invention is a difunctional block-polymer of poly (ethylene glycol) (PEG) and poly (propylene glycol) (PPG) .
- PEG poly (ethylene glycol)
- PPG poly (propylene glycol)
- Such non-ionic polymers are sold under the tradename of Pluronics by BASF.
- Preferred polaxamers have a block of PPG surrounded by blocks of PEG, in accordance with this formula:
- a most preferred poloxamer has the CTFA designation of Poloxamer 407. Mixtures of poloxamers may also be employed.
- the total amount of poloxamer is preferably from 0.1 to 20%, more preferably from 0.5 to 10%, and especially from 1 to 3% by weight of the total composition.
- the sensory benefits, in particular those of foam quality and quantity, delivered by the present invention may be sensitive to the relative amounts anionic surfactant, amphoteric surfactant, and poloxamer employed.
- the ratio of the sum of the total amounts of anionic and amphoteric surfactant to the total amount of poloxamer is from 1:5 to 5:1, more preferably from 1:2 to 2:1, and most preferably from 0.8:1.2 to 1.2:0.8 by weight.
- a highly preferred additional component in compositions of the invention is an abrasive.
- the abrasive may contribute to the in use sensory properties.
- Suitable abrasives are particulate materials such as silica, alumina, calcium carbonate, dicalciumphosphate, calcium pyrophosphate, hydroxyapatite (HAP) , trimetaphosphate, insoluble hexametaphosphate, or mixtures thereof.
- Agglomerated particulate abrasive materials may also be used.
- Preferred abrasive materials are chalk and silica, in particular silica.
- HAP is also a preferred additional component and especially HAP of morphology as described in WO 03/000588 (BASF) .
- the total amount of abrasive is typically from 3 to 60%, in particular from 5 to 40%, and especially from 6% to 20% by weight of the total composition.
- compositions of the invention may deliver a humectancy benefit; however, it is highly preferred that compositions of the invention comprise an additional humectant such as an additional polyol, in particular an additional polyol selected from glycerol, sorbitol, propyleneglycol, xylitol, lactitol, or mixtures thereof. Sorbitol is especially preferred, this material also functioning as a sweetener (vide infra) .
- the poloxamer is typically from 1 to 60%, in particular from 5 to 50%, and especially from 10% to 30% by weight of the total composition.
- composition according to the invention may comprise further ingredients.
- Rheological modifiers are preferred further ingredients that often contribute to the in use sensory properties of the composition.
- Preferred additional ingredients of this type are thickening agents, in particular cellulose derivatives (such sodium carboxymethylcellulose [SCMC]), polyethylene glycols, and thickening silicas (such as Tixosil 43 , ex Rhodia) .
- Other thickening agents are xanthan gum, gum Arabic, synthetic polyacrylates, and synthetic carboxyvinyl polymers (such as Carbopol E ) .
- Vitamins sources in particular sources of vitamin E, such as vitamin E acetate are a preferred further ingredient.
- Additional antimicrobial agents i.e. in addition to the zinc salt that is an essential component of compositions of the invention, may also be included.
- examples include organic anti-microbials (such as triclosan or chlorhexidine) , copper salts, stannous salts (such as stannous pyrophosphate) , sanguinarine extract, metronidazole, quaternary ammonium compounds (such as cetylpyridinium chloride) , bis-guanides (such as chlorhexidine) , digluconate, hexetidine, octenidine, alexidine; and halogenated bisphenolic compounds (such as 2,2' -methylenebis- (4-chloro-6-bromophenol) ) .
- Anti-caries agents are further ingredients that may be advantageously employed in compositions of the invention. Examples of such agents include sodium and stannous fluoride, aminefluorides, sodium monofluorophosphate, sodium trimetaphosphate and casein.
- Polymeric compounds which can enhance the delivery of active ingredients, such as antimicrobial agents, can also be included.
- examples of such polymers are copolymers of polyvinylmethylether with maleic anhydride and other similar delivery enhancing polymers, e.g. those described in DE-A- 3, 942, 643 (Colgate) .
- non-ionic surfactants i.e. in addition to the poloxamer, which is often classified as such
- cationic surfactants may also be included, as might cationic surfactants.
- plaque buffers such as urea, calcium lactate, calcium glycerophosphate and strontium polyacrylates
- anti-inflammatory agents such as ibuprofen, flurbiprofen, aspirin, and indomethacin;
- desensitising agents such as potassium citrate, potassium chloride, potassium tartrate, potassium bicarbonate, potassium oxalate, potassium nitrate and strontium salts; anti-calculus agents, such as alkali-metal pyrophosphates, hypophosphite-containing polymers, organic phosphonates and phosphocitrates;
- bio-molecules such as bacteriocins, antibodies, and enzymes ;
- proteinaceous materials such as collagen
- sweetening agents such as saccharin and sorbitol (vide supra) ;
- bleaching agents such as peroxy compounds (e.g. potassium peroxydiphosphate) ;
- compositions of the invention e.g. starch, sucrose, water or water/alcohol systems.
- Water is a particularly preferred pharmaceutically acceptable carrier and is typically present in compositions of the invention at from 5 to 95%, in particular 15 to 75%, and especially at from 35 to 60% by weight of the total composition.
- compositions indicated in Table 1 were prepared by standard methods known in the art.
- a performance evaluation test of the compositions indicated in Table 1 was carried in order to evaluate user perceptions of the products. 20 trained panellists were employed and asked to evaluate the toothpastes across a range of attributes using a 0 to 10 line scale. The average results concerning selected attributes are indicated in Table 2.
- Example 1 Compared with Example A, Example 1 gave significantly better texture in use; significantly higher flavour intensity, both in use and after use; and significantly reduced astringency after use. Compared with Example B, Example 1 gave significantly higher foam quantity and foam quality in use. The indicated differences were significant at the 95% level of confidence.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
Abstract
An oral care composition: a zinc salt, an anionic surfactant, an amphoteric surfactant, and a poloxamer.
Description
ORAL CARE COMPOSITION
The present invention relates to oral care compositions comprising zinc salts and having superior sensory benefits.
Oral care compositions comprising zinc are known in the art. EP-Al-O 740 932 (Unilever) discloses a gel type dentifrice comprising a zinc salt which is more water soluble than zinc citrate. US 5,470,561 (Klugkist) discloses an anti-plaque mouthwash comprising a zinc salt and triclosan. GB 2,052,978 (Unilever) discloses a toothpaste comprising zinc salts with glycine. US 5,632,972 (Williams) discloses a method for minimising damage to gingival and periodontal tissue by delivering a first component comprising zinc and a second component comprising a bicarbonate. US 4 325 939 (Shah) discloses an alkali metal or ammonium zinc citrate prepared for use in dental compositions and especially in mouthwash compositions. US 5,188,820 (Cummins et al) discloses oral compositions comprising a mixture of a stannous salt and a zinc salt such as zinc citrate.
Oral care compositions comprising surfactants, such anionic, non-ionic, or amphoteric surfactants are also known in the art. 02/26203 (Henkel, 2002) discloses dental cleaning agents comprising surfactants or tensides in the form of a combination of anionic tensides, betaine tensides, and ethoxylated fatty acid-polyol monoesters. WO 95/01173 (Unilever, 1995) and US 6,169,118 (Unilever, 2001) disclose amphoteric surfactants in toothpaste compositions.
Also known in the art are oral care compositions comprising non-ionic polymers, such as poly (ethylene glycol) - poly (propylene glycol) block co-polymers, known as "poloxamers". Such compositions are described in US 6,187,295 (P&G, 2001) .
We have found that by carefully selecting particular components from amongst those mentioned above, it is possible to formulate oral care compositions comprising zinc salts that have superior sensory properties and other properties. In particular, we have found it possible to formulate toothpaste compositions that have superior texture, flavour, and reduced astringency without compromising sensory perceptions of foam quantity and foam quality.
In a first of aspect of the present invention, there is provided an oral care composition comprising a zinc salt, an anionic surfactant, an amphoteric surfactant, and a poloxamer.
In a second of aspect of the present invention, there is provided a method of cleaning the teeth comprising brushing with a composition according to the first aspect of the invention.
In a third of aspect of the present invention, there is provided the use of a poloxamer to improve the in use foam quantity and/or quality of an oral care composition also comprising a zinc salt, an anionic surfactant and an amphoteric surfactant.
The sensory benefits given by compositions according to the invention are found both in use and after use. We have found that compositions according to the invention are perceived to have good texture in use and also good foam quantity and foam quality. In addition, compositions according to the invention give high flavour intensities both in use and after use and low astringency after use. It is believed that these benefits are related to the particular combination of surfactants and non-ionic polymer selected for use in the compositions of the invention.
The oral care compositions of the present invention may take any of the forms commonly used for such purpose; however, toothpastes are a particularly suitable form.
The zinc salt used in accordance with this invention may give benefits associated with its anti-microbial properties, such as reduced gingivitis, plaque, sensitivity, and/or bad breath.
A problem encountered with some prior art compositions comprising zinc salts has been a relatively high level of astringency. This problem, amongst others, is at least partially overcome by the compositions of the present invention.
The zinc salt used in accordance with the invention is typically soluble in water, meaning that it has a solubility in water of at least 0.1 g/1 at 25°C. Preferably, the zinc salt has a solubility in water at 25°C of at least 1 g/1 and more preferably at least 2 g/1. Particularly preferred zinc
salts are zinc citrate, zinc sulphate, glycinate, and zinc chloride. Mixtures of zinc salts may also be employed. Zinc citrate is the most preferred zinc salt for use in the compositions of the invention.
The total amount of zinc salts is typically from 0.1 to 10%, in particular from 0.5 to 5%, and especially from 1 to 3% by weight of the total composition.
The anionic surfactant used in accordance with the invention is preferably an alkali metal alkyl sulphate, more preferably a sodium linear alkyl (Cio-Ciβ) sulphate, and most preferably sodium lauryl sulphate (SLS) . Mixtures of anionic surfactants may also be employed.
The total amount of anionic surfactant is preferably from 0.1 to 10%, more preferably from 0.2 to 5%, and especially from 0.5 to 2% by weight of the total composition.
The amphoteric surfactant used in accordance with the invention is preferably a betaine, more preferably an alkylamidopropyl betaine (wherein the alkyl group is a linear Cio~Ci8 chain) , and most preferably is cocoamidopropyl betaine (CAPB) . Mixtures of amphoteric surfactants may also be employed.
The total amount of amphoteric surfactant is preferably from 0.1 to 10%, more preferably from 0.2 to 5%, and especially from 0.5 to 2% by weight of the total composition.
The poloxamer used in accordance with the invention is a difunctional block-polymer of poly (ethylene glycol) (PEG) and poly (propylene glycol) (PPG) . Such non-ionic polymers are sold under the tradename of Pluronics by BASF. Preferred polaxamers have a block of PPG surrounded by blocks of PEG, in accordance with this formula:
HO- (ECOa-(PO)b- (EO) a-H
wherein EO = CH2-CH2-O; PO = CH2-CH (CH3) -0; and a:b = from 1:2 to 5:1.
Preferred poloxamers of the above formula have a:b = from 1:1 to 3:1, especially when a = from 80 to 120 and b = from 40 to 70.
A most preferred poloxamer has the CTFA designation of Poloxamer 407. Mixtures of poloxamers may also be employed.
The total amount of poloxamer is preferably from 0.1 to 20%, more preferably from 0.5 to 10%, and especially from 1 to 3% by weight of the total composition.
The sensory benefits, in particular those of foam quality and quantity, delivered by the present invention may be sensitive to the relative amounts anionic surfactant, amphoteric surfactant, and poloxamer employed. Thus, it is preferred that the ratio of the sum of the total amounts of anionic and amphoteric surfactant to the total amount of
poloxamer is from 1:5 to 5:1, more preferably from 1:2 to 2:1, and most preferably from 0.8:1.2 to 1.2:0.8 by weight.
A highly preferred additional component in compositions of the invention is an abrasive. In some compositions, the abrasive may contribute to the in use sensory properties. Suitable abrasives are particulate materials such as silica, alumina, calcium carbonate, dicalciumphosphate, calcium pyrophosphate, hydroxyapatite (HAP) , trimetaphosphate, insoluble hexametaphosphate, or mixtures thereof.
Agglomerated particulate abrasive materials may also be used. Preferred abrasive materials are chalk and silica, in particular silica. HAP is also a preferred additional component and especially HAP of morphology as described in WO 03/000588 (BASF) .
When employed, the total amount of abrasive is typically from 3 to 60%, in particular from 5 to 40%, and especially from 6% to 20% by weight of the total composition.
The poloxamer used in accordance with the present invention may deliver a humectancy benefit; however, it is highly preferred that compositions of the invention comprise an additional humectant such as an additional polyol, in particular an additional polyol selected from glycerol, sorbitol, propyleneglycol, xylitol, lactitol, or mixtures thereof. Sorbitol is especially preferred, this material also functioning as a sweetener (vide infra) .
When employed, the total amount of additional humectant
(i.e. excluding the poloxamer) is typically from 1 to 60%,
in particular from 5 to 50%, and especially from 10% to 30% by weight of the total composition.
The composition according to the invention may comprise further ingredients. Rheological modifiers are preferred further ingredients that often contribute to the in use sensory properties of the composition. Preferred additional ingredients of this type are thickening agents, in particular cellulose derivatives (such sodium carboxymethylcellulose [SCMC]), polyethylene glycols, and thickening silicas (such as Tixosil 43 , ex Rhodia) . Other thickening agents are xanthan gum, gum Arabic, synthetic polyacrylates, and synthetic carboxyvinyl polymers (such as CarbopolE) .
Vitamins sources, in particular sources of vitamin E, such as vitamin E acetate are a preferred further ingredient.
Additional antimicrobial agents, i.e. in addition to the zinc salt that is an essential component of compositions of the invention, may also be included. Examples include organic anti-microbials (such as triclosan or chlorhexidine) , copper salts, stannous salts (such as stannous pyrophosphate) , sanguinarine extract, metronidazole, quaternary ammonium compounds (such as cetylpyridinium chloride) , bis-guanides (such as chlorhexidine) , digluconate, hexetidine, octenidine, alexidine; and halogenated bisphenolic compounds (such as 2,2' -methylenebis- (4-chloro-6-bromophenol) ) .
Anti-caries agents are further ingredients that may be advantageously employed in compositions of the invention. Examples of such agents include sodium and stannous fluoride, aminefluorides, sodium monofluorophosphate, sodium trimetaphosphate and casein.
Polymeric compounds which can enhance the delivery of active ingredients, such as antimicrobial agents, can also be included. Examples of such polymers are copolymers of polyvinylmethylether with maleic anhydride and other similar delivery enhancing polymers, e.g. those described in DE-A- 3, 942, 643 (Colgate) .
Additional non-ionic surfactants (i.e. in addition to the poloxamer, which is often classified as such) may also be included, as might cationic surfactants.
Other ingredients that may be incorporated include:
plaque buffers, such as urea, calcium lactate, calcium glycerophosphate and strontium polyacrylates;
anti-inflammatory agents, such as ibuprofen, flurbiprofen, aspirin, and indomethacin;
desensitising agents, such as potassium citrate, potassium chloride, potassium tartrate, potassium bicarbonate, potassium oxalate, potassium nitrate and strontium salts;
anti-calculus agents, such as alkali-metal pyrophosphates, hypophosphite-containing polymers, organic phosphonates and phosphocitrates;
bio-molecules, such as bacteriocins, antibodies, and enzymes ;
proteinaceous materials, such as collagen;
preservatives;
opacifying agents;
colouring agents;
pH-adjusting agents;
sweetening agents, such as saccharin and sorbitol (vide supra) ;
bleaching agents, such as peroxy compounds (e.g. potassium peroxydiphosphate) ;
buffers and salts to buffer the pH and ionic strength of the composition; and
pharmaceutically acceptable carriers, e.g. starch, sucrose, water or water/alcohol systems. Water is a particularly preferred pharmaceutically acceptable carrier and is typically present in compositions of the invention at from 5
to 95%, in particular 15 to 75%, and especially at from 35 to 60% by weight of the total composition.
Examples
In the following examples, comparative examples are indicated by letters and examples according to the invention are indicated by numbers. All amounts of components are indicated as percentages by weight.
The compositions indicated in Table 1 were prepared by standard methods known in the art.
Table 1
A performance evaluation test of the compositions indicated in Table 1 was carried in order to evaluate user perceptions of the products. 20 trained panellists were employed and asked to evaluate the toothpastes across a range of attributes using a 0 to 10 line scale. The average results concerning selected attributes are indicated in Table 2.
Table 2
Compared with Example A, Example 1 gave significantly better texture in use; significantly higher flavour intensity, both in use and after use; and significantly reduced astringency after use. Compared with Example B, Example 1 gave significantly higher foam quantity and foam quality in use. The indicated differences were significant at the 95% level of confidence.
Claims
1. An oral care composition comprising a zinc salt, an anionic surfactant, an amphoteric surfactant, and a poloxamer.
2. A composition according to claim 1, further comprising an abrasive.
3. A composition according to claim 1 or 2, further comprising a humectant.
4. A composition according to any of the proceeding claims, wherein the amphoteric surfactant is a betaine.
5. A composition according to claim 4, wherein the amphoteric surfactant is a linear alkyl (Cio-Ciβ) amidopropyl betaine.
6. A composition according to any of the proceeding claims, wherein the poloxamer has a block of poly (propylene glycol) surrounded by blocks of poly (ethyelene glycol), in accordance with this formula : HO- (EO)a- (PO)b- (EO)a-H wherein EO = CH2-CH2-O; PO = CH2-CH (CH3) -0; and a:b = from 1:2 to 5:1.
7. A composition according to claim 6, wherein the poloxamer is Poloxamer 407.
8. A composition according to any of the preceding claims, wherein the ratio of the sum of the total amounts of anionic and amphoteric surfactant to the total amount of poloxamer is from 1:2 to 2:1 by weight.
9. A method of cleaning the teeth comprising brushing with a composition according to any of the preceding claims.
10. The use of a poloxamer to improve the in use foam quantity and/or quality of an oral care composition also comprising a zinc salt, an anionic surfactant and an amphoteric surfactant.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07109276.1 | 2007-05-31 | ||
EP07109276 | 2007-05-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008145475A1 true WO2008145475A1 (en) | 2008-12-04 |
WO2008145475A8 WO2008145475A8 (en) | 2009-03-05 |
Family
ID=38581975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/055398 WO2008145475A1 (en) | 2007-05-31 | 2008-05-01 | Oral care composition |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008145475A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009117643A3 (en) * | 2008-03-21 | 2009-11-26 | Colgate-Palmolive Company | Compositions comprising nonionic and zwitterionic surfactants |
JP2013159604A (en) * | 2012-02-09 | 2013-08-19 | Lion Corp | Dentifrice composition |
US8568697B2 (en) | 2008-03-21 | 2013-10-29 | Colgate-Palmolive Company | High fluoride ion recovery compositions |
WO2012106016A3 (en) * | 2011-02-04 | 2013-11-07 | Colgate-Palmolive Company | Oral care compositions |
WO2013034414A3 (en) * | 2011-09-09 | 2013-12-12 | Henkel Ag & Co. Kgaa | Special toothpaste for electric tooth brushes i |
WO2013020960A3 (en) * | 2011-08-09 | 2014-03-20 | Glaxo Group Limited | Novel composition |
WO2014088575A1 (en) * | 2012-12-06 | 2014-06-12 | Colgate-Palmolive Company | Surfactant systems for zinc containing compositions |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990015592A1 (en) * | 1989-06-12 | 1990-12-27 | Patrick John Shanahan | Anti-plaque dentifrice |
WO1991007163A1 (en) * | 1989-11-15 | 1991-05-30 | The Gillette Company | Stabilized stannous fluoride compositions for oral care |
US5073368A (en) * | 1991-05-15 | 1991-12-17 | Colgate-Palmolive Company | Sanguinaria mouthrinse having improved anti microbial activity and stability |
US5104644A (en) * | 1990-02-07 | 1992-04-14 | 7-L Corporation | Mouthrinse composition |
US5653964A (en) * | 1991-12-20 | 1997-08-05 | Block Drug Company Inc. | Dentinal desensitizing compositions |
-
2008
- 2008-05-01 WO PCT/EP2008/055398 patent/WO2008145475A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990015592A1 (en) * | 1989-06-12 | 1990-12-27 | Patrick John Shanahan | Anti-plaque dentifrice |
WO1991007163A1 (en) * | 1989-11-15 | 1991-05-30 | The Gillette Company | Stabilized stannous fluoride compositions for oral care |
US5104644A (en) * | 1990-02-07 | 1992-04-14 | 7-L Corporation | Mouthrinse composition |
US5073368A (en) * | 1991-05-15 | 1991-12-17 | Colgate-Palmolive Company | Sanguinaria mouthrinse having improved anti microbial activity and stability |
US5653964A (en) * | 1991-12-20 | 1997-08-05 | Block Drug Company Inc. | Dentinal desensitizing compositions |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8568697B2 (en) | 2008-03-21 | 2013-10-29 | Colgate-Palmolive Company | High fluoride ion recovery compositions |
WO2009117643A3 (en) * | 2008-03-21 | 2009-11-26 | Colgate-Palmolive Company | Compositions comprising nonionic and zwitterionic surfactants |
CN107049831A (en) * | 2011-02-04 | 2017-08-18 | 高露洁-棕榄公司 | Oral care composition |
CN103547317A (en) * | 2011-02-04 | 2014-01-29 | 高露洁-棕榄公司 | oral care composition |
JP2014505701A (en) * | 2011-02-04 | 2014-03-06 | コルゲート・パーモリブ・カンパニー | Oral care composition |
AU2011357693B2 (en) * | 2011-02-04 | 2015-07-09 | Colgate-Palmolive Company | Oral care compositions |
US10667995B2 (en) | 2011-02-04 | 2020-06-02 | Colgate-Palmolive Company | Oral care compositions |
WO2012106016A3 (en) * | 2011-02-04 | 2013-11-07 | Colgate-Palmolive Company | Oral care compositions |
WO2013020960A3 (en) * | 2011-08-09 | 2014-03-20 | Glaxo Group Limited | Novel composition |
US11723853B2 (en) | 2011-08-09 | 2023-08-15 | Block Drug Company Inc. | Composition |
US11000465B2 (en) | 2011-08-09 | 2021-05-11 | Block Drug Company, Inc. | Composition |
US10548827B2 (en) | 2011-08-09 | 2020-02-04 | Glaxo Group Limited | Composition |
US9693939B2 (en) | 2011-09-09 | 2017-07-04 | Henkel Ag & Co. Kgaa | Toothpaste for electric toothbrushes |
WO2013034414A3 (en) * | 2011-09-09 | 2013-12-12 | Henkel Ag & Co. Kgaa | Special toothpaste for electric tooth brushes i |
JP2013159604A (en) * | 2012-02-09 | 2013-08-19 | Lion Corp | Dentifrice composition |
RU2622022C2 (en) * | 2012-12-06 | 2017-06-08 | Колгейт-Палмолив Компани | Systems of surfactants for zinc-containing compositions |
TWI556834B (en) * | 2012-12-06 | 2016-11-11 | 美國棕欖公司 | Surfactant systems for zinc containing compositions |
AU2012396297B2 (en) * | 2012-12-06 | 2015-08-20 | Colgate-Palmolive Company | Surfactant systems for zinc containing compositions |
CN104822360A (en) * | 2012-12-06 | 2015-08-05 | 高露洁-棕榄公司 | Surfactant systems for zinc containing compositions |
WO2014088575A1 (en) * | 2012-12-06 | 2014-06-12 | Colgate-Palmolive Company | Surfactant systems for zinc containing compositions |
Also Published As
Publication number | Publication date |
---|---|
WO2008145475A8 (en) | 2009-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012396297B2 (en) | Surfactant systems for zinc containing compositions | |
CN104853729B (en) | Two components compositions comprising zinc and amino-acids halide complex and cysteine | |
US20080152599A1 (en) | Oral care compositions | |
WO2008145475A1 (en) | Oral care composition | |
US20220401321A1 (en) | Oral Care Compositions | |
JP5512791B2 (en) | Desensitizing dentifrice showing antibacterial uptake of dental tissue | |
JP3753868B2 (en) | Oral composition | |
JP3855103B2 (en) | Oral composition | |
US20030068283A1 (en) | Composition | |
JP3803868B2 (en) | Oral composition | |
US20030215403A1 (en) | Oral composition | |
US20050063920A1 (en) | Oral composition | |
ES2279619T3 (en) | TRANSPARENT DENTIFRIC GELS. | |
JP3803869B2 (en) | Oral composition | |
EP3621699B1 (en) | Oral care compositions | |
US20030068282A1 (en) | Composition | |
US6436372B2 (en) | Oral composition with abrasive mixture of chalk and carbide | |
US20100226865A1 (en) | Toothpaste composition | |
WO2020212099A1 (en) | A personal care composition comprising piperlongumine and process for producing the composition | |
WO2020207633A1 (en) | Oral care composition comprising gingerdiol and process for producing the composition | |
WO2018206172A1 (en) | Oral care compositions | |
WO2006005420A1 (en) | Tooth whitening composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08749972 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08749972 Country of ref document: EP Kind code of ref document: A1 |